As blockbuster GLP-1 injectables like Mounjaro, Wegovy and Ozempic gain traction in India, doctors stress that careful ...

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. The U.S. Food and Drug Administration (FDA) recently ...

GLP-1s are driving traditional drug spending in the U.S. to unprecedented levels, which now outpaces specialty drug spending for the first time, according to a March 25 report from Evernorth. The ...

GLP-1 drugs like Ozempic and Mounjaro have significant health benefits for type 1 diabetes, including weight loss, despite ...

Not sure what to expect when starting on a GLP-1? Get insights on how long it may take to start working, what results may be, and more. But these medications aren’t new. They’ve been around for ...

On the heels of STRIDE, one of the first trials to show glucagon-like peptide-1 (GLP-1) receptor agonists can help patients with PAD, a retrospective study of more than 100,000 patients provides more ...

Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...

GLP-1 receptor agonists like semaglutide and tirzepatide have redefined what’s possible in the treatment of obesity and metabolic syndrome. These medications have shown remarkable results in appetite ...

As the buzz around GLP-1 medications grew to a fever pitch over the past two years, many digital health and telehealth companies quickly added programs to prescribe anti-obesity drugs. Omada Health ...

Glucagon-like peptide-1 (GLP-1) agonists have transformed weight loss treatments. However, about half of the patients who take these drugs stop within a year because of unwanted side effects. 1,2 For ...

Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry ...